Latest News Release

Oncolytics Biotech Inc. Announces REOLYSIN® Phase I Clinical Trial Interim Results

Oncolytics Announces Webcast of REOLYSIN® Phase I Interim Results Conference Call

Oncolytics Biotech Inc. Announces REOLYSIN(R) Systemic Animal Toxicology Results

Oncolytics Biotech Inc. Completes Enrollment For REOLYSIN® Phase I Clinical Trial

ONCOLYTICS BIOTECH INC. ANNOUNCES THIRD QUARTER RESULTS

Oncolytics Biotech, Inc. to Present at Techvest, LLC Emerging Healthcare Forum

Oncolytics Biotech Inc. Announces Approval to Proceed with Clinical Trial to Evaluate REOLYSIN(R) for the Treatment of Prostate Cancer

Oncolytics Biotech Inc. Begins Trading on NASDAQ Small Cap Market Today


Year

Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas Read More

Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer Read More

View all news articles

Exploring REOLYSIN®’s Objective Response Rate in Females with Colorectal Cancer Read More

Exploring REOLYSIN<sup>®</sup>’s Objective Response Rate in Females with Colorectal Cancer thumbail
View all blog posts

LATEST TWEETS

Sorry, there was a problem. Twitter returned the following error message:

Could not authenticate you.

Follow us on Twitter